MajesTEC-7: A Phase 3, Randomized Study of Teclistamab plus Daratumumab plus Lenalidomide (Tec-DR) Versus Daratumumab plus Lenalidomide plus Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant

被引：13

作者：

Krishnan, Amrita Y. ^{[1
]}

Manier, Salomon ^{[2
]}

Terpos, Evangelos ^{[3
]}

Usmani, Saad ^{[4
]}

Khan, Josephine ^{[5
]}

Pearson, Rachel ^{[5
]}

Girgis, Suzette ^{[6
]}

Guo, Yue ^{[6
]}

McAleer, Dana ^{[6
]}

Olyslager, Yunsi ^{[7
]}

Kampfenkel, Tobias ^{[8
]}

van de Donk, Niels W. C. J. ^{[9
]}

机构：

[1] City Hope Comprehens Canc Ctr, Duarte, CA USA

[2] Univ Lille, Lille, France

[3] Univ Athens, Athens, Greece

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Janssen Res & Dev, High Wycombe, Bucks, England

[6] Janssen Res & Dev, Spring House, PA USA

[7] Janssen Res & Dev, Beerse, Belgium

[8] Janssen Res & Dev, Neuss, Germany

[9] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-160173

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：10148 / 10149

页数：2

共 50 条

[1] MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab plus daratumumab plus lenalidomide (EDR) versus daratumumab plus lenalidomide plus dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).
Grosicki, Sebastian
Yeh, Su-Peng
Huang, Jeffrey S. Y.
Byun, Ja Min
DiRienzo, Christine
Viqueira, Andrea
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab plus daratumumab plus lenalidomide (EDR) versus daratumumab plus lenalidomide plus dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)
Kull, M.
Grosicki, S.
Yeh, S. -P.
Huang, J. S. Y.
Byun, J. M.
DiRienzo, C.
Viqueira, A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 314 - 314
[3] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Jakubowiak, Andrzej
Usmani, Saad Z.
Krishnan, Amrita
Lonial, Sagar
Comenzo, Raymond L.
Wang, Jianping
de Boer, Carla
Deraedt, William
Weiss, Brendan M.
Schecter, Jordan M.
Chari, Ajai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10) : 701 - 710
[4] Phase 3 randomized study of Daratumumab plus lenalidomide and Dexamethasone (D-Rd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA)
Weisel, K.
Facon, T.
Kumar, S.
Plesner, T.
Orlowski, R. Z.
Moreau, P.
Bahlis, N.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Mace, J. R.
Ahmadi, T.
Chiu, C.
Wang, J.
van Rampelbergh, R.
Uhlar, C. M.
Kobos, R.
Qi, M.
Usmani, S. Z.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 194 - 194
[5] Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)
Facon, Thierry
Kumar, Shaji K.
Plesner, Torben
Orlowski, Robert Z.
Moreau, Philippe
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Mace, Joseph R.
Ahmadi, Tahamtan
Chiu, Christopher
Wang, Jianping
Van Rampelbergh, Rian
Uhlar, Clarissa M.
Kobos, Rachel
Qi, Ming
Usmani, Saad Z.
BLOOD, 2018, 132
[6] MajesTEC-4: Phase 3 trial of Teclistamab plus Lenalidomide versus Lenalidomide in patients with newly diagnosed multiple myeloma
Cook, Gordon
Zamagni, Elena
Boccadoro, Mario
Spencer, Andrew
Delforge, Michel
Reece, Donna
Szabo, Agoston Gyula
Einsele, Hermann
Terpos, Evangelos
Schjesvold, Fredrik
Bila, Jelena
Driessen, Christoph
Beksac, Meral
Rodriguez, Cesar
Pei, Lixia
Shi, Yingqi
Sakabedoyan, Caline
Jasielec, Jagaoda
Amin, Himal
Kobos, Rachel
Sonneveld, Pieter
Van De Donk, Niels
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 57 - 57
[7] Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study
Usmani, Saad Z.
Facon, Thierry
Hungria, Vania
Bahlis, Nizar J.
Venner, Christopher P.
Braunstein, Marc
Pour, Ludek
Marti, Josep M.
Basu, Supratik
Cohen, Yael C.
Matsumoto, Morio
Suzuki, Kenshi
Hulin, Cyrille
Grosicki, Sebastian
Legiec, Wojciech
Beksac, Meral
Maiolino, Angelo
Takamatsu, Hiroyuki
Perrot, Aurore
Turgut, Mehmet
Ahmadi, Tahamtan
Liu, Weiping
Wang, Jianping
Chastain, Katherine
Vermeulen, Jessica
Krevvata, Maria
Lopez-Masi, Lorena
Carey, Jodi
Rowe, Melissa
Carson, Robin
Zweegman, Sonja
NATURE MEDICINE, 2025, : 1195 - 1202
[8] Isatuximab Plus Lenalidomide and Dexamethasone With Bortezomib Versus Isatuximab Plus Lenalidomide and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma: The Benefit Study
Leleu, Xavier
Hulin, Cyrille
Lambert, Jerome
Bobin, Arthur
Perrot, Aurore
Manier, Salomon
Jaccard, Arnaud
Montes, Lydia
Karlin, Lionel
Godmer, Pascal
Chalopin, Thomas
Slama, Borhane
Chretien, Marie Lorraine
Laribi, Karim
Dingremont, Claire
Roul, Christophe
Mariette, Clara
Rigaudeau, Sophie
Macro, Margaret
Mohty, Mohamad
Touzeau, Cyrille
Moreau, Philippe
Avet-Loiseau, Herve
Corre, Jill
Facon, Thierry
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S33 - S33
[9] Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Thierry Facon
Gordon Cook
Saad Z. Usmani
Cyrille Hulin
Shaji Kumar
Torben Plesner
Cyrille Touzeau
Nizar J. Bahlis
Supratik Basu
Hareth Nahi
Hartmut Goldschmidt
Hang Quach
Mohamad Mohty
Christopher P. Venner
Katja Weisel
Noopur Raje
Benjamin Hebraud
Karim Belhadj-Merzoug
Lotfi Benboubker
Olivier Decaux
Salomon Manier
Denis Caillot
Jon Ukropec
Huiling Pei
Rian Van Rampelbergh
Clarissa M. Uhlar
Rachel Kobos
Sonja Zweegman
Leukemia, 2022, 36 : 1066 - 1077
[10] Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
Facon, Thierry
Kumar, Shaji K.
Weisel, Katja
Usmani, Saad
Moreau, Philippe
Plesner, Torben
Orlowski, Robert Z.
Bahlis, Nizar Jacques
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Carson, Robin
Borgsten, Fredrik
Goldschmidt, Hartmut
BLOOD, 2022, 140 : 10133 - 10136

← 1 2 3 4 5 →